Blackstone Inc’s ImmunityBio IBRX Stock Holding History

Blackstone Inc’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,944	Closed	-$29.4K	–	275
2025 Q3	$29.4K	Buy	+11,944	New	+$30.8K	﹤0.01%	248
2021 Q2	–	Sell	-58,009	Closed	-$1.38M	–	624
2021 Q1	$1.38M	Buy	+58,009	New	+$1.5M	﹤0.01%	336

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Blackstone Inc's IBRX Position: Q4 2025 in Review

Blackstone Inc sold out of ImmunityBio (IBRX) in Q4 2025, closing a stake of 11,944 shares — an estimated $29.4K sold.

Blackstone Inc first reported a position in IBRX in Q1 2021 and held it in 2 quarters. The position peaked at $1.38M in Q1 2021. 278 funds tracked by Wall St. Rank hold IBRX as of Q4 2025.

Blackstone Inc reported no remaining ImmunityBio position as of Q4 2025 after selling out during the quarter.
Blackstone Inc sold 11,944 ImmunityBio shares in Q4 2025, an estimated $29.4K.
Blackstone Inc first reported a position in ImmunityBio in Q1 2021 and held it in 2 quarters.
Blackstone Inc's ImmunityBio position peaked at $1.38M in Q1 2021.
278 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2025.

Based on Blackstone Inc's 13F filing for Q4 2025, filed 17 Feb 2026.